These include: Semaglutide (Wegovy) recommended by NICE for weight management in eligible adults (NICE TA875) Liraglutide (Saxenda) recommended by NICE for weight management in selected groups (NICE TA664) Orlistat available for weight management under NICE guidance (NICE CG189) Naltrexone/bupropion (Mysimba) does not currently have a positive NICE recommendation for weight management in England and should not be assumed to be a routinely recommended option
Additional sources: Drugs.com history (development timeline, phase 3 updates)
ConciergeMD Consultation Retatrutide is not yet commercially available, but ConciergeMD offers personalized weight management consultations that include peptide therapy, lifestyle guidance, and medical supervision
This isn't a marginal supplement category or an emerging fringe treatment - it's a class of prescription medications with a robust clinical trial data package that informed medical consensus supports for weight management in qualifying patients
PubMed Aronne, L.J., Sattar, N., Horn, D.B., Bays, H.E., Wharton, S., Lin, W.Y., Ahmad, N.N., Zhang, S., Liao, R., Bunck, M.C., Jouravskaya, I., Hesse, D., Jastreboff, A.M., & SURMOUNT-1 Investigators
Pregnancy & Breastfeeding: Women who are pregnant, breastfeeding, or planning to conceive in the next 2 months (medication must be stopped beforehand)
